1047P AXA-042, a systemically administered TLR2/6 agonist, demonstrates target engagement and TLR pathway activation in patients with advanced solid tumors. - Tran, B.; Millward, M.; Lemech, C.; Frentzas, S.; Day, D.; Latifi, A.; Desai, J.; Wabnitz, P.; Kearney, P.; Galkin, A. (Annals of Oncology, 2023)